We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Fastforward Innovations Limited | FFWD | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 8.25 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 8.25 |
| Top Posts |
|---|
Posted at 30/6/2021 11:29 by 888icb $FFWD ‘s portfolio company,@PortageBiotech , has been added to the Russell 2000® Index which is widely used by investment managers, institutional investors & as benchmarks for active investment strategies. Read more here: [...] #Healthcare. The news flow continues on many fronts with value being added by the portfolio of investments. The new cannabis strategy is working really well demonstrating how quickly value can be added in the pre IPO space that can’t be accessed by PI’s. That was the original purpose of FFWD and it is very pleasing that Ed is now doing what it said on the tin. |
Posted at 23/6/2021 18:25 by yogaboy 888 I agree with your #13056: it certainly reflects my position waiting for the Leap liquidity event before I cash in.Now that the change in FFWD’s investment approach has been clearly stated, I can’t see their exit strategy from the new portfolio. So other than spreading risk in medical cannabis investment, there’s nothing more here to attract investors like me. Here’s hoping that Leap will have been worth waiting for. I expect so, and don’t think we will have to wait too long now. |
Posted at 23/6/2021 10:33 by 888icb Ian Burns continued, "We are positioning the company, which was originally incorporated in 2006, for the next exciting phase in its development, by bringing its constituent documents up to date to reflect changes in company law and into line with current market expectations, readying it for future investment, including from institutional investors should NAV and market cap develop as hoped."I think this statement shows that the Company intends to seek institutional investment once it gets the market cap above £50 million which tends to be the point at which institutions will invest. It looks like a good plan as the company refocuses after the Leap sale and should provide an exit at a good price for those who don’t want to continue down the Cannabis route or just want to realise some profit. |
Posted at 10/6/2021 13:36 by monkeymonkey i thought series C Was no longer, just a few big investors to join when as ? |
Posted at 27/5/2021 18:09 by bdog51 Ed McDermott tweet from this afternoon, 27 May at 15:03 -There remains a huge disconnect between our stated NAV (many months old now) and our share price. As communicated already #FFWD investors can expect the following. - New investments v soon- PF support- multiple IPOs including #Leap which is 43% owned by FFWD |
Posted at 19/5/2021 09:02 by 888icb Time to take a Leap into FastForward Innovations ask @TMSreachToday 07:06“…WeR The biggest frustration for the chief executive of FastForward Innovations is not being able to buy more stock. The company makes investments in disruptive businesses that aren’t trendy, toppy and transient in nature, but have substance, make a difference not just to innovation recipients, but investors. Ed McDermott has been CEO of this VC fund for over three years and has never been busier as he assesses opportunities in hemp based wellness, life science, medicinal cannabis, blockchain, edtech and 3D gaming. This former boxer and keen angler has stamina and patience, but was aware that the stellar board needed further strengthening and from grassroots level. This year’s significant hire is Alfredo Pascual the man with a medical cannabis networking black book par excellence. While investors await news about the well telegraphed IPO of investee company Leap Gaming, Pascual is looking for opportunities to augment the company’s portfolio and maintain its position as a credible, cashful corporation. FFWD Podcast interview. (Link at bottom of page) As Ed explains to Sarah Lowther, #FFWD has already delivered on its net asset value promises and there’s more investment news flow to come with the company being in a ‘very strong position’ and the company eventually becoming it’s own news-flow machine. hxxps://total-market ReplyRecommend An interview that is a must listen for anyone interested in FFWD and will be 18 minutes well spent. |
Posted at 11/3/2021 11:42 by 888icb I think we will see the large increases in market cap this year because we have now reached the time for liquidity events in our early investments. Ed mentioned the 2 main drivers of the market cap and he knows what Leap should produce as he has all the accounting information as a Director of Leap.I think it is very useful to understand the history of FFWD as this gives further confidence in why I think it will deliver a good return. FFWD was set up by Jim Mellon inspired by his book of the same name to invest in companies at pre ipo stages not available to normal private investors. So you need people like Jim Mellon and high net worth investors who have access to those opportunities. Look at who our large shareholders are and look at their involvement as Directors and large shareholders in the companies FFWD has invested in. They will all make more money the sale of the underlying investments but will also want to make a return on the money they have had invested for years many at considerably higher share prices than today’s. In the early days the 2 main drivers were Jim Mellon and Lorne Abony both of whom were Directors. Over time both resigned as Directors to concentrate on the underlying investments which have all performed very well. But I also suspect they both resigned to avoid the potential conflicts of interests inherent in being Directors of the Investee companies as well as FFWD. So we then have Ed’s arrival on the scene and we are aware of his links to Lorne. So while Ed doesn’t have any shares himself there are a number of large shareholders who he won’t want to disappoint. Everything points to Leap delivering this year and with a 44% stake the lions share of the profits have to come to FFWD to put the original large shareholders into profit. |
Posted at 12/2/2021 19:40 by dave4545 Seems volumes are rapidly improving today for Yooma.Maybe Yooma can be our version of Rms, start of stuck around a certain level then it takes off once those in from the start have took their profits and sold out, always takes a few days for new investors to clear out pre Ipo investors. |
Posted at 23/9/2020 11:33 by 888icb UP 9.3% on volume of 350000 and 22 trades. Good to see today’s RNS which reminds us we have some serious investors holding big chunks of the company. They have stuck with the company despite large falls in the value of their holdings. They understand the investments that FFWD has made and have been prepared to wait for them to come good. We are now at that point where a number of investments are very close to liquidity events. These long term investors will have paid 15p and higher I think in the case of today’s RNS investor. These investors will need the share price to be well above 25p to even see a half decent return on their investment but will have invested expecting a lot more from these early stage investments.It is looking very promising and one hopes today’s rise is evidence that the market is starting to take notice. |
Posted at 17/11/2019 16:22 by dillondon1 Brief synopsis of Longevity WeekWords are from a Longevity CEO who was present I was recently in London for the Longevity Week, a collection of single day and evening events organized by investor Jim Mellon of Juvenescence and supporting groups. Varied events focused separately on (a) educating investors in the science of aging, (b) generating a larger investment community for the new longevity industry, and (c) improving the non-profit world and its efforts to explain the merits of treating aging to the public, to bring therapies to the clinic, and to improve the state of older life using presently available tools. Jim Mellon clearly understands that building an industry focused on the medical control of aging, particularly in regions where medical development and clinical practice is so very heavily regulated, requires raising the water level when it comes to understanding of that industry and its potential. The first event, the Science Summit, was a small and selective gathering that I was kindly invited to. It was the successor to an earlier master class on the science of aging organized for an audience of investors interested in the field, based on the concept that investors, and then the field as a whole, will benefit from a better understanding of the underlying science. I should say that these are largely investors in funds rather than investors in companies, occupying the higher valuation end of the investment community. These are people who, collectively as a class, have a lot of influence over the shape and pace of development of future industries through their choices in what to invest in. The second event, Investing in the Age of Longevity, was a part of the investor-focused programs organized by Jim Mellon's Master Investor organization, a way to promote understanding of - and participation in - the longevity industry among the members of the broader investor community. This is of course of great benefit to Juvenescence, cofounded by Jim Mellon, but it is also of great benefit to everyone else. If we are to see this industry thrive and deliver on the promise of treating aging as a medical condition, it absolutely must be promoted and made interesting to the investment community. The final event was the yearly Longevity Forum, in which the focus is on non-profits, governments, and the process of explaining the promise of treating aging as a medical condition to society at large. Alongside the three days of events were evening gatherings of folk in the longevity community, a chance to catch up with people who are working on interesting projects, or funding those interesting projects. Much of the more important networking happens outside the events, as is ever the case. It was an interesting week, all told, and it is clear that we're all going to be very much better off in the years ahead as a result of the efforts of Jim Mellon and his allies and staff. This is a step up in the scale of advocacy for the treatment of aging in comparison to past years. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
